Clene’s (CLNN) cash and cash equivalents totaled $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its resources as of March 31, 2025, will be sufficient to fund its operations into the third quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Optimistic Outlook on Clene’s CNM-Au8 for ALS: Investment Potential Amid Clinical Challenges
- Clene initiated with a Buy at JonesResearch
- Promising Potential of Clene’s CNM-Au8 in MS: Analyst Recommends Buy Rating
- Clene Showcases CNM-Au8® Advancements at Neurology Session
- Clene announces evidence of remyelination, neuronal repair with CNM-Au8